Literature DB >> 12918115

Construction and characterization of bivalent vaccine candidate expressing HspA and M(r)18,000 OMP from Helicobacter pylori.

Zheng Jiang1, Ai-Long Huang, Xiao-Hong Tao, Pi-Long Wang.   

Abstract

AIM: To construct a recombinant vector which can express outer membrane protein (OMP) with M(r)18,000 and heat shock protein A (HspA) from Helicobacter pylori (H. pylori) in E. coli BL21, and to exploit the possibility for obtaining the vaccine conferring protection from H. pylori infection.
METHODS: The target gene of HspA was amplified from H. pylori chromosome by PCR, and then inserted into the prokaryotic expression vector pET32a (+) by restrictive endonuclease enzyme kpn I, BamH I simultaneously. The recombinant vector was used to sequence, and then together with pET32a (+)/Omp(18), digested by restrictive endonuclease enzyme Hind III and BamH I simultaneously. pET32a(+)/HspA and Omp(18) were recovered from 1 % agarose gel by gel kit, and ligated with T(4) ligase by BamH I digested viscidity end. The recombinant plasmid of pET32a(+)/HspA/Omp(18) was transformed and expressed in E. coli BL21 (DE3) under induction of IPTG. After purification, its antigenicity of the fusion protein was detected by Western blot.
RESULTS: Enzyme digestion analysis and sequencing showed that the target genes were inserted into the recombinant vector, composed of 891 base pairs, encoded objective polypeptides of 297 amino acid residues. Compared with GenBank reported by Tomb et al, there were 1.3 % and 1.4 % differences in obtained H. pylori nucleotide sequence and amino acid residues, respectively. SDS-PAGE analysis showed that relative molecule mass (M(r)) of the expressed product was M(r) 51,000, M(r) of protein expressed by pET32a (+) was about M(r) 20,000, and soluble expression product accounted for 18.96 % of total bacterial protein. After purification with Ni(+2)-NTA agarose resins, the purification of recombinant fusion protein was about 95 %. Western blot showed that recombinant fusion protein could be recognized by the patients' serum infected with H. pylori and anti-Omp(18) monoclone, suggesting that this protein had good antigenicity.
CONCLUSION: The gene coding for H. pylori M(r)18,000 OMP and HspA was cloned and expressed successfully. The results obtained lay the foundation for development of H. pylori protein vaccine and a quick diagnostic kit.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12918115      PMCID: PMC4611538          DOI: 10.3748/wjg.v9.i8.1756

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN: 1007-9327            Impact factor:   5.742


  59 in total

1.  Helicobacter pylori and Behçet's disease.

Authors:  O Avci; E Ellidokuz; I Simşek; B Büyükgebiz; A T Güneş
Journal:  Dermatology       Date:  1999       Impact factor: 5.366

2.  Clinicopathological features of gastric mucosa-associated lymphoid tissue lymphoma: a comparison with diffuse large B-cell lymphoma without a mucosa-associated lymphoid tissue lymphoma component.

Authors:  T Hiyama; K Haruma; Y Kitadai; H Masuda; M Miyamoto; M Ito; T Kamada; S Tanaka; N Uemura; M Yoshihara; K Sumii; F Shimamoto; K Chayama
Journal:  J Gastroenterol Hepatol       Date:  2001-07       Impact factor: 4.029

3.  Urease-based mucosal immunization against Helicobacter heilmannii infection induces corpus atrophy in mice.

Authors:  C Dieterich; H Bouzourène; A L Blum; I E Corthésy-Theulaz
Journal:  Infect Immun       Date:  1999-11       Impact factor: 3.441

4.  Immune response induced by recombinant BCG expressing merozoite surface antigen 2 from Plasmodium falciparum.

Authors:  C Zheng; P Xie; Y Chen
Journal:  Vaccine       Date:  2001-12-12       Impact factor: 3.641

5.  HIV mucosal vaccine: nasal immunization with rBCG-V3J1 induces a long term V3J1 peptide-specific neutralizing immunity in Th1- and Th2-deficient conditions.

Authors:  T Hiroi; H Goto; K Someya; M Yanagita; M Honda; N Yamanaka; H Kiyono
Journal:  J Immunol       Date:  2001-11-15       Impact factor: 5.422

6.  Peroral immunization with Helicobacter pylori adhesin protein genetically linked to cholera toxin A2B subunits.

Authors:  B O Kim; S S Shin; Y H Yoo; S Pyo
Journal:  Clin Sci (Lond)       Date:  2001-03       Impact factor: 6.124

Review 7.  Helicobacter pylori vaccine strategies--triggering a gut reaction.

Authors:  C Hatzifoti; B W Wren; W J Morrow
Journal:  Immunol Today       Date:  2000-12

8.  A study of recombinant protective H.pylori antigens.

Authors:  Zheng Jiang; Xiao-Hong Tao; Ai-Long Huang; Pi-Long Wang
Journal:  World J Gastroenterol       Date:  2002-04       Impact factor: 5.742

Review 9.  Helicobacter pylori and idiopathic chronic urticaria.

Authors:  E Daudén; I Jiménez-Alonso; A García-Díez
Journal:  Int J Dermatol       Date:  2000-06       Impact factor: 2.736

10.  Manipulation of immune responses to Mycobacterium bovis by vaccination with IL-2- and IL-18-secreting recombinant bacillus Calmette Guerin.

Authors:  Sarah Young; Michael O'Donnell; Euan Lockhart; Bryce Buddle; Lynn Slobbe; Yi Luo; Geoff De Lisle; Glenn Buchan
Journal:  Immunol Cell Biol       Date:  2002-06       Impact factor: 5.126

View more
  3 in total

1.  Construction of an oral recombinant DNA vaccine from H pylori neutrophil activating protein and its immunogenicity.

Authors:  Bo Sun; Zhao-Shen Li; Zhen-Xing Tu; Guo-Ming Xu; Yi-Qi Du
Journal:  World J Gastroenterol       Date:  2006-11-21       Impact factor: 5.742

Review 2.  Research progress on Helicobacter pylori outer membrane protein.

Authors:  Shi-He Shao; Hua Wang; Shun-Gen Chai; Li-Mei Liu
Journal:  World J Gastroenterol       Date:  2005-05-28       Impact factor: 5.742

3.  The rOmp22-HpaA fusion protein confers protective immunity against helicobacter pylori in mice.

Authors:  Xueyong Huang; Bianli Xu; Guangcai Duan; Chunhua Song
Journal:  Curr Microbiol       Date:  2013-05-30       Impact factor: 2.188

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.